Ipsen Signs Cancer Drug Deal With Active Biotech Ahead Of Strategic Review

Ipsen has signed a deal with Active Biotech, gaining rights to market its prostate cancer product in all territories excluding North and South America and Japan. This is the first purely drug-focused deal under a new CEO, but ahead of a strategic review at the end of Q2 there is little evidence that this will become a trend.